Skip to main content Deutsch


Gerd  Jomrich Gerd Jomrich

Department of General Surgery (Division of Visceral Surgery)
Position: Consultant

ORCID: 0000-0002-7294-4831
T +43 1 40400 56210

Further Information


Barrett Esophagus; Carcinoma, Pancreatic Ductal; Esophageal Neoplasms; Esophagectomy; Esophagogastric Junction; Fibroblast Growth Factors; Gastrectomy; Gastroesophageal Reflux; Inflammation; Neoadjuvant Therapy; Pancreatic Cancer; Pancreatic Neoplasms; Pancreaticoduodenectomy; Pancreatitis; Receptors, Fibroblast Growth Factor; Translational Medical Research

Research interests

  • Expression of Fibroblast Growth Factors and its Receptors in (neoadjuvantly treated) Esophageal and Pancreatic Cancer
  • Prognostic Value of preoeprative Laboratory Results in Esophageal and Pancreatic Cancer
  • Biobanking: Establishing a Biobank for Upper-GI and Pancreatic Malignancies
  • Perioperative stress-induced biomarkers on stress signaling receptors in Esophageal and Pancreatic Cancer patients

Techniques, methods & infrastructure

  • Upper-GI Biobank
  • Pancreatic Cancer Biobank
  • Analyzing Esophageal and Pancreatic Cancer RNASeq Data from TCGA (The Cancer Genome Atlas)
  • Immunohistochemistry (IHC)
  • Quantitative RT-PCR
  • Retrospective Clinical Studies

Selected publications

  1. Jomrich, G. et al., 2019. High Mean Corpuscular Volume Predicts Poor Outcome for Patients With Gastroesophageal Adenocarcinoma. Annals of Surgical Oncology, 26(4), pp.976–985. Available at:
  2. Jomrich, G. et al., 2018. MK2 and ETV1 Are Prognostic Factors in Esophageal Adenocarcinomas. Journal of Cancer, 9(3), pp.460–468. Available at:
  3. Jomrich, G. & Schoppmann, S., 2015. Targeting HER 2 and angiogenesis in gastric cancer. Expert Review of Anticancer Therapy, 16(1), pp.111-122. Available at:
  4. Jomrich, G. et al., 2019. Systemic Immune-Inflammation Index (SII) Predicts Poor Survival in Pancreatic Cancer Patients Undergoing Resection. Journal of Gastrointestinal Surgery. Available at:
  5. Kollmann, D. et al., 2018. PD-L1 expression is an independent predictor of favorable outcome in patients with localized esophageal adenocarcinoma. OncoImmunology, 7(6), p.e1435226. Available at: